

1 **Title:** Access to routinely collected health data for clinical trials – review of successful data requests
2 to UK registries

3

4 **Authors**

5 Sarah Lensen, Research Fellow

6 MRC CTU at UCL WC1V 6LJ

7 Health Data Research UK

8 s.lensen@ucl.ac.uk

9 ORCID: 0000-0002-1694-1142

10 Archie Macnair, Clinical Research Fellow

11 MRC CTU at UCL WC1V 6LJ

12 a.macnair@ucl.ac.uk

13 ORCID: 0000-0001-5429-9114

14 Sharon B Love, Associate Professor

15 MRC CTU at UCL WC1V 6LJ

16 s.love@ucl.ac.uk

17 ORCID: 000-0002-6695-5390

18 Victoria Yorke-Edwards, Research Fellow

19 MRC CTU at UCL WC1V 6LJ

20 v.yorke-edwards@ucl.ac.uk

21 ORCID: 0000-0002-6465-7330

22 Nurulamin M Noor, PhD candidate

23 MRC CTU at UCL WC1V 6LJ

24 nurulamin.noor.18@ucl.ac.uk

25 ORCID: is 0000-0003-3426-6408

26 Meredith Martyn, PhD candidate

27 MRC CTU at UCL WC1V 6LJ

28 Meredith.martyn.17@ucl.ac.uk

29 ORCID: 0000-0002-2342-6771

30 Alexandra Blenkinsop, PhD candidate

31 MRC CTU at UCL WC1V 6LJ

32 Alexandra.blenkinsop.16@ucl.ac.uk

33 ORCID: 0000-0002-2328-8671

34 Carlos Diaz-Montana, Clinical Data Systems Manager

35 MRC CTU at UCL WC1V 6LJ

36 c.diaz@ucl.ac.uk

37 ORCID: 0000-0001-9082-4596

38 Graham Powell, Clinical Research Fellow

39 Department of Molecular and Clinical Pharmacology, University of Liverpool, L69 3BX

40 Graham.powell@liverpool.ac.uk

41 ORCID: 0000-0003-3840-2534

42 Elizabeth Williamson, Associate Professor

43 London School of Hygiene and Tropical Medicine WC1E 7HT

44 Elizabeth.williamson@lshtm.ac.uk

45 ORCID: 0000-0001-6905-876X

46 James Carpenter¹, Professor,

47 Medical Statistics, London School of Hygiene and Tropical Medicine WC1E 7HT, and

48 MRC CTU at UCL WC1V 6LJ

49 j.carpenter@ucl.ac.uk

50 ORCID: 0000-0003-3890-6206

51 Matthew R Sydes¹, Professor,
52 MRC CTU at UCL WC1V 6LJ
53 m.sydes@ucl.ac.uk
54 ORCID: 0000-0002-9323-1371

55

56 ¹These authors contributed equally

57

58 **Correspondence to:** Sharon Love s.love@ucl.ac.uk

59 **ABSTRACT**

60

61 **Background:** Clinical trials generally each collect their own data despite routinely-collected health
62 data (RCHD) increasing in quality and breadth. Our aim is to quantify UK-based randomised
63 controlled trials (RCTs) accessing RCHD for participant data, characterise how these data are used
64 and thereby recommend how more trials could use RCHD.

65 **Methods:** We conducted a systematic review of RCTs accessing RCHD from at least one registry in
66 the UK between 2013-2018, for the purposes of informing or supplementing participant data. A list
67 of all registries holding RCHD in the UK was compiled. In cases where registries published release
68 registers, these were searched for RCTs accessing RCHD. Where no release register was available,
69 registries were contacted to request a list of RCTs. For each identified RCT, information was collected
70 from all publicly available sources (release registers, websites, protocol etc.). The search and data
71 extraction was undertaken between Jan-2019 and May-2019.

72 **Results:** We identified 160 RCTs accessing RCHD between 2013 and 2018 from a total of 22
73 registries; this corresponds to only a very small proportion of all UK RCTs (approximately 3%). RCTs
74 accessing RCHD were generally large (median sample size 1590), commonly evaluating treatments

75 for cancer or cardiovascular disease. Most of the included RCTs accessed RCHD from NHS Digital
76 (68%), and the most frequently accessed datasets were mortality (76%) and hospital visits (55%).
77 RCHD was used to inform the primary trial (82%) and long-term follow-up (57%). There was
78 substantial variation in how RCTs used RCHD to inform participant outcome measures. A limitation
79 was the lack of information and transparency from registries and RCTs with respect to which
80 datasets have been accessed and for what purposes.

81 **Conclusions:** In the last five years, only a small minority of UK-based RCTs have accessed RCHD to
82 inform participant data. We ask for improved accessibility, confirmed data quality and joined up
83 thinking between the registries and the regulatory authorities.

84 **Registration:** PROSPERO CRD42019123088

85 **Keywords:** Systematic review, Routinely-collected health data, registry, RCT

86 **BACKGROUND**

87 Randomised controlled trials (RCTs) are the gold-standard method for evaluating healthcare
88 interventions, and their results impact on policy, practice, and patient care. Substantial resources
89 are dedicated to collection of trial data and participant follow-up. Consequently the costs of
90 conducting large trials are substantial, maybe in the order of millions of pounds (1). However many
91 national databases and registries collect data which map to common important healthcare events
92 such as hospital admission, cancer registration and death. Use of this routinely-collected health data
93 (RCHD) to replace or supplement traditional data capture should reduce trial costs, enabling a
94 greater number of large, definitive trials and efficient long-term assessment of healthcare
95 interventions.

96 This explains why the use of RCHD in RCTs has been labelled as a disruptive technology i.e. a
97 technology which transforms current practice (2). A model exemplar is the TASTE trial, which
98 randomised 7244 participants in two years within national Swedish registries, collected participant

99 data from registries and yielded high impact results at a fraction of the cost of traditional RCTs (USD
100 \$300,000 or \$50 per patient)(3, 4). The UK holds a large number of rich health datasets, linkable
101 through a unique National Health Service (NHS) number. The availability of these datasets is
102 growing, as are the technological capabilities of processing and storing this data. In response to this,
103 Health Data Research (HDR) UK was established with the ambition to unleash the potential of RCHD
104 to deliver “Better, Faster and More Efficient Trials” (5).

105 However, while RCHD is already being harnessed to enhance UK RCTs, anecdotal evidence suggests
106 substantial barriers remain. Therefore, this systematic review set out to identify and characterise
107 RCTs accessing RCHD in the UK to inform participant data, to describe how RCTs use these data, and
108 to prioritise issues which need to be addressed

109

110 **METHODS**

111 A systematic review of RCTs which have accessed RCHD to inform or supplement trial data.

112

113 *Eligibility*

114 RCHD was defined as data which are collected for “administrative and clinical purposes without
115 specific a priori research goals” (6). This included large, national, administrative resources (e.g. NHS
116 Digital), national disease and healthcare audits and registries in each UK devolved nation (e.g. the
117 National Emergency Laparotomy Audit). Hereafter we refer to these collectively as registries. Cohort
118 studies, biobanks, NHS Safe Havens and electronic health records held only at the point of care, such
119 as primary care records held within general practitioner (GP) practices, were excluded.

120

121 Eligible RCTs received RCHD from a registry between 2013 and 2018. This time-frame was selected
122 to broadly align with the initiation of release registers in large national databases following the 2014

123 Partridge Review (7). For each included RCT, any additional access to RCHD from another registry
124 and any previous access of RCHD prior to 2013 was also captured.

125

126 Eligible RCTs were those which accessed RCHD to inform either baseline or outcome measure data
127 of trial participants. For at least one outcome measure, RCHD must have been used for any
128 combination of: (i) replacing conventionally collected trial data; (ii) cross-checking against existing
129 trial data (including participant-reported data); (iii) cross-checking RCHD from different sources; (iv)
130 triggering the trial team to further investigate a possible outcome measure or event; (v) cost-
131 effectiveness analysis and (vi) solely methodological purposes. This was captured separately for (a)
132 the primary reporting period of the trial (i.e. baseline data or an outcome measure within the follow-
133 up for capturing the primary trial outcome measure) and (b) for long-term follow-up.

134

135 We excluded RCTs if the RCHD was only accessed to plan or facilitate recruitment, e.g. to contact
136 patients with an invitation of RCT enrolment, or to extrapolate results of RCTs to broader
137 populations. The Protocol for this review was registered with PROSPERO at the stage of screening
138 and data collection (CRD42019123088, registered 20 Feb 2019).

139

140 ***RCT identification***

141 First, we compiled a list of registries (healthcare databases, registries and audits) in the UK through
142 internet searching, the Health Quality Improvement Program (HQIP) directory (8), contact with
143 government and contracted organisations, and existing knowledge of UK registries (more
144 information on registries approached in additional file [[additional file 1](#)]). Release registers were
145 identified where possible; these are lists of all data released from a given registry, often including
146 the purpose for which the data will be used and the specific datasets accessed. Where these were
147 not available, registries were contacted to request a list of RCTs to which they had released RCHD.

148 Release registers from each source were de-duplicated prior to screening (to remove multiple
149 instances of data releases for the same RCT from an individual registry). The resultant list was then
150 searched for eligible RCTs by filtering for entries containing one or more of the following terms:
151 rand*, trial, RCT, study, placebo, phase. The search results were then screened independently for
152 potentially eligible RCTs by two authors. Disagreements were resolved by discussion and re-
153 checking.

154

155 ***Data collection and analysis***

156 For each RCT identified, we sought information from within the release registers (e.g. ‘purpose
157 statements’), RCT websites (including privacy statements, publications, protocols, statistical analysis
158 plans, patient information sheets and consent forms), and other available sources including trial
159 registration information. Publications for each RCT were searched for in major dissemination
160 databases (e.g. MEDLINE, Google Scholar). More information about data collection is given in an
161 additional file [\[additional file 4\]](#).

162 Data collection included information about the RCT (e.g. disease category, recruitment and
163 publication status, primary outcome measure), the registry (e.g. NHS Digital), the RCHD accessed
164 (e.g. Hospital Episode Statistics), and the way in which the data were used (e.g. linkage identifiers
165 used, category of data use). Due to the large number of RCTs identified, we focussed more detailed
166 data collection of information on the datasets accessed and the way in which the data were used to
167 RCTs accessing RCHD between 2017 and 2018. Two authors independently extracted data onto a
168 piloted data extraction form and any disagreements were resolved by discussion and re-checking.
169 Data were subsequently entered into a clinical data management system (Elsevier’s MACRO (9)) and
170 descriptive analyses were undertaken in Stata (version 15.1)(10). Trial teams were not contacted for
171 information or clarification.

172 To enable a broad comparison of this cohort of RCTs with those conducted in the UK, we compared
173 the descriptive characteristics of these RCTs with those reported in a recent cross-sectional analysis
174 of UK Health Research Authority (HRA) approved RCTs (11).

175

176 ***Patient and public involvement***

177 No patients were involved in any component of the design, production, analysis, interpretation or
178 writing up of the results of this review. We plan to disseminate the final results to the HDR UK Public
179 Advisory Board, and request they disseminate the manuscript within their network as appropriate.

180

181 **RESULTS**

182 ***Results of the search***

183 The search and extraction of data was undertaken between Jan-2019 and May-2019. 74 UK registries
184 holding RCHD were identified, of which 13 maintained accessible release registers ([Figure 1](#)).

185 **Figure 1. Identification of trials from registries**

186 Caption: Each trial is only counted once. For instance, trials identified through both release register
187 searches and notification by registries are only captured once. Of 13 registries with release registers
188 available, 10 published comprehensive release registers and 3 provided a brief lists of projects
189 receiving RCHD on the website.

190 These release registers listed more than 6,000 unique data releases. There were 2,918 releases
191 identified in the search. These were manually screened and 141 RCTs were identified; corresponding
192 to 2% (141/6251) of the total releases. The remaining 61 registries were contacted to request
193 information about RCTs having accessed RCHD, resulting in a further 19 RCTs identified from eight
194 registries. During the data extraction, we discovered one trial that had received data from one of the
195 registries which had not otherwise provided a list of trials. This gave a total of 160 RCTs accessing
196 RCHD from 22 registries between 2013 and 2018 ([Figure 1](#)). Although all RCTs had accessed RCHD

197 between 2013 and 2018, they were conducted in varying time periods, with recruitment start dates
198 ranging from 1979 to 2018. Detailed data collection, for trials accessing data in 2017-18, involved
199 91/160 trials.

200

201 ***RCT characteristics***

202 The 160 included RCTs were generally large (median sample size 1590, range 41 – 6,000,000),
203 although 11% (17/160) described themselves as pilot or feasibility trials ([Table 1](#)). The majority (85%,
204 136/160) were individually randomised trials and 15% (24/160) were cluster randomised. The most
205 common disease categories were cancer (29%, 47/160) and cardiovascular disease (29%, 46/160),
206 and the most common primary outcome measure was survival/death (45%, 72/160). Only 20%
207 (32/160) of the RCTs were international, recruiting at additional sites outside of the UK. A small
208 number of RCTs had publications available which included outcome measures informed by access to
209 RCHD. Of these, 83% (29/35) had one or more results publication in a high profile medical journal.

210 The majority of RCTs were clearly coordinated through a UK Clinical Research Collaboration (UKCRC)
211 Registered Clinical Trials Unit (64%, 103/160 coordinated by a registered CTU, 14%, 22/160 were
212 not, 22%, 35/160 were unclear) ([Table 1](#)). Of all 51 currently registered CTUs, 63% (32/51) had
213 accessed RCHD for at least one RCT in this cohort. Of these CTUs, the median number of RCTs from
214 this cohort was 2 (range 1-11).

215 RCTs accessing RCHD were more often conducted in cancer and cardiovascular populations
216 compared to RCTs submitted for an ethical opinion via the HRA in 2015 (29% vs 10%, and 29% vs
217 17%, respectively), were more likely to recruit from primary care settings (26% vs 5%), to be based
218 only in the UK (78% vs 50%) and to be cluster-randomised (15% vs 3%). RCHD RCTs had larger
219 sample sizes on average (median 1590 vs 275) than those submitted to the HRA ([Table 2](#)). RCTs
220 accessing RCHD were less likely to be feasibility/pilot studies (11% vs 18%). We identified 160 trials

221 accessing RCHD over a five-year period (32 trials per year), which is equivalent to approximately 3%
 222 (32/963) of all RCTs approved by the HRA in 2015.

223 **RCHD access and use**

224 NHS Digital was by far the most commonly accessed registry: 68% (108/160) trials accessed RCHD
 225 from NHS Digital ([Table 3](#)).

226 **Table 3. Registries and datasets accessed**

Registry	Total Trials n=160	Total Trials (2017-2018) n=91	Datasets accessed Total Trials (2017-2018) n=91			
			Death n=69	Hospital visits n=50	Cancer registration n=29	Other n=26
NHS-Digital	108 (68%)	59 (65%)	58 (84%)	34 (68%)	22 (76%)	4 (15%)
ISD-Scotland	35 (22%)	25 (27%)	16 (23%)	13 (26%)	7 (24%)	2 (8%)
PHE	15 (9%)	11 (12%)	3 (4%)	6 (12%)	10 (34%)	1 (4%)
SAIL	9 (6%)	6 (7%)	2 (3%)	5 (10%)	2 (7%)	1 (4%)
ICNARC	7 (4%)	4 (4%)	1 (1%)	0 (0%)	0 (0%)	4 (15%)
NWIS	7 (4%)	6 (7%)	1 (1%)	6 (12%)	1 (3%)	0 (0%)
PICANet	6 (4%)	2 (2%)	0 (0%)	0 (0%)	0 (0%)	2 (8%)
CPRD	4 (3%)	1 (1%)	0 (0%)	1 (2%)	0 (0%)	1 (4%)
NHSBT	3 (2%)	3 (3%)	0 (0%)	0 (0%)	0 (0%)	2 (8%)
TARN	3 (2%)	2 (2%)	1 (1%)	1 (2%)	0 (0%)	2 (8%)
NELA	2 (1%)	2 (2%)	0 (0%)	0 (0%)	0 (0%)	2 (8%)
NNRD	2 (1%)	2 (2%)	1 (1%)	1 (2%)	0 (0%)	2 (8%)
PHW	2 (1%)	1 (1%)	0 (0%)	0 (0%)	0 (0%)	1 (4%)
UKRR	2 (1%)	2 (2%)	0 (0%)	1 (2%)	1 (3%)	0 (0%)
ResearchOne	2 (1%)	2 (2%)	0 (0%)	0 (0%)	0 (0%)	2 (8%)
DOH	1 (1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
FFFAP	1 (1%)	1 (1%)	0 (0%)	0 (0%)	0 (0%)	1 (4%)
HBS	1 (1%)	1 (1%)	0 (0%)	0 (0%)	0 (0%)	1 (4%)
NICOR	1 (1%)	1 (1%)	1 (1%)	0 (0%)	0 (0%)	0 (0%)
NICR	1 (1%)	1 (1%)	0 (0%)	0 (0%)	1 (3%)	0 (0%)
OHCAO	1 (1%)	1 (1%)	0 (0%)	0 (0%)	0 (0%)	1 (4%)
UKCFR	1 (1%)	1 (1%)	0 (0%)	0 (0%)	0 (0%)	1 (4%)

227

228 Caption: Registries accessed was captured for all 160 trials. Information about datasets accessed
 229 from these registries was captured only for those 91 accessing RCHD between 2017 and 2018. The
 230 fields are not mutually exclusive as one trial may have accessed data from multiple registries; and
 231 multiple datasets can be accessed via a single registry. Percentages are calculated using the column
 232 header denominators. Hospital visits includes all Hospital Episode Statistics (Outpatient, Inpatient,
 233 Accident and Emergency, and Critical Care), Patient Episode Database for Wales (PEDW), and
 234 Scottish Morbidity Records (SMR). Acronyms: Information Services Division (ISD), Public Health
 235 England (PHE), Secure Anonymised Information Linkage (SAIL), Intensive Care National Audit &
 236 Research Centre (ICNARC), NHS Wales Informatics Service (NWIS), Paediatric Intensive Care Audit

237 Network (PICANet), Clinical Practice Research Datalink (CPRD), NHS Blood and Transplant (NHSBT),
238 Trauma Audit and Research Network - Major Trauma Audit (TARN), National Emergency Laparotomy
239 Audit (NELA), Neonatal Research Database (NNRD), Public Health Wales (PHW), UK Renal Registry
240 (UKRR), Department of Health (DOH), Falls and Fragility Fractures Audit programme (FFFAP), Honest
241 Broker Service, Northern Ireland Statistics and Research Agency (HBS) , National Institute for
242 Cardiovascular Outcomes Research (NICOR), Northern Ireland Cancer Registry (NICR), Out-of-
243 Hospital Cardiac Arrest Outcomes (OHCAO) Registry, UK Cystic Fibrosis Registry (UKCFR)

244

245 The second most common was Information Services Division in Scotland 22%, 35/160). Most of the
246 RCTs accessed RCHD from one registry (79%, 126/160); 14% (22/160) accessed data from two
247 registries, 5% (8/160) from 3 registries, and 3% (4/160) from 4 or more. A small number of RCTs
248 were completely embedded (i.e. participants were recruited from and followed-up) in the registry
249 (12%, 11/91).

250

251 Of the 160 RCTs, 91 had received a total of 134 data releases in the years 2017-2018 and were
252 selected for detailed data extraction. Identifiers used for linkage were often unclear (46%, 62/134),
253 however when assessable, the most common fields were NHS Number (94%, 68/72), date of birth
254 (85%, 61/72) and participant name (56%, 40/72) (an additional file shows [Table S2 \[additional file](#)
255 [2\]](#)). The most common datasets accessed were mortality (76%, 69/91), hospital visits (55%, 50/91)
256 and cancer registration (32%, 29/91) ([Table 3](#)). Almost half of the included RCTs (47%, 43/91)
257 accessed RCHD to inform the primary trial outcome measure. Of RCTs using RCHD only for at least
258 one outcome measure, 38% (20/52) were drug trials.

259

260 36 out of 91 RCTs (40%, 36/91) accessed RCHD for both the primary and long-term follow-up ([Table](#)
261 [4](#)); 21% (19/91) of RCTs accessed one or more RCHD only for long-term follow-up and 45% (41/91)
262 accessed one or more RCHD exclusively for the primary with no obvious planned long-term follow-
263 up.

264 Most commonly, RCHD alone was used for at least one trial outcome measure (57%, 52/91) ([Table](#)
265 [4](#)). One third of RCTs used RCHD for cross-checking, either of trial data (30%, 27/91) or participant-
266 reported data (31%, 28/91). Use of RCHD to trigger case review was also common (24%, 22/91), as
267 was use of the data to conduct cost-effectiveness analysis (27%, 25/91). Use of RCHD for
268 methodological reasons was uncommon (12%, 11/91), as was release for comparison of two or more
269 RCHD sources (10%, 9/91). RCTs using RCHD for long-term follow-up were more likely to use RCHD
270 alone to inform outcome measures, and less likely to conduct cross-checking against trial or
271 participant-reported data, or to use the data for methodological purposes. Overall, there was
272 substantial variation in how trials used RCHD to inform participant outcome measures. For example,
273 among the 74 trials using RCHD within the primary reporting period, 37 different combinations of
274 data use were captured (an additional file shows [Table S3 \[additional file 3\]](#)). Among the 36 RCTs
275 using RCHD for the primary report and long-term follow-up, 56% (20/36) used the data differently
276 for these two stages of the study for at least one outcome measure, for example shifting from cross-
277 checking of trial data for the primary reporting to RCHD only during the long-term follow-up.

278

279 **DISCUSSION**

280 The increase in the scope, accessibility, and richness of RCHD presents an unprecedented
281 opportunity for better health research(12). Use of RCHD for trial outcome measures may be a cost-
282 effective means of obtaining data, limiting the burden on trial staff and participants in attending for
283 trial visits or replying to questionnaires, especially for longer-term data collection. Use of RCHD may
284 also minimise attrition in RCTs where datasets have national coverage, reduce issues of self-reported
285 outcome measures which are prone to recall bias (e.g. recalling diagnoses or operations from
286 hospital visits), and could limit ascertainment bias where the clinicians and coders are not aware of
287 trial participation. However, are RCHD replacing case report forms in clinical trials and, if not, why
288 not?

289 To the best of our knowledge, this is the first review to summarise the accessing of RCHD by
290 randomised trials in the UK by reviewing the sources of data, and the first to assess the use of these
291 data specifically for trial outcome measure assessment. We identified 160 trials accessing RCHD to
292 inform participant data from 22 registries in the UK between 2013 and 2018, with many (47%,
293 43/91) using it for the primary outcome measure. This corresponds to approximately 32 trials a year,
294 which is about 3% of the trials seeking HRA approval annually (11). Alongside this, RCTs accessing
295 RCHD accounted for only 2% of the data releases from included registries. Since most trial patient
296 data are captured in the hospital records, this suggests the potential of RCHD in trials is largely
297 untapped.

298 We observed considerable variation in the use of RCHD, most commonly to inform or supplement
299 outcome measures in primary trial report and long-term follow-up. Only 52/91 (57%) used RCHD
300 alone for the collection of at least one trial outcome measure i.e. even when used, the data are
301 duplicated from trial-specific sources – further evidence that the potential of RCHD is largely
302 unrealised.

303 Only a very small proportion of UK trials appear to be successfully accessing RCHD. Our findings are
304 consistent with anecdotal evidence that one barrier to greater access and use may be lack of
305 awareness among trialists regarding the availability and potential utility of this information for trial
306 follow-up. There is no national directory of registries which lists sources of RCHD available to
307 researchers. The National Institute for Health Research (NIHR) Health Data Finder for Research
308 contains only 18 datasets (18). Half of the registries identified for this review confirmed they had not
309 provided data to RCTs and may represent an underutilised resource.

310 Both for us (as reviewers) and for trialists, the lack of a comprehensive list of RCHD registries and the
311 data they hold, is a challenge. Further, the majority of registries we identified did not maintain a
312 register of approved data releases. A number of release registers had brief information (e.g. only
313 application titles), and some registries were unable to advise whether their RCHD had been released

314 for this purpose. Therefore, our search may have missed eligible trials. For trialists, this makes it
315 more difficult to keep abreast of how these data may be used, hindering the uptake of RCHD by the
316 community. A further barrier is that many publications about the included trials which were
317 expected to include RCHD, made no mention of it. So it was often not clear from publically-available
318 sources exactly how RCHD would be used with a trial (note we deliberately did not contact trial
319 teams for information or clarification, as our aim was to assess information which was publically
320 available). The forthcoming CONSORT extension for RCTs using cohorts and accessing electronic
321 health records should help to improve transparency in reporting (13) and enable the community to
322 keep abreast of developments.

323 Other recent reviews in this area have summarised characteristics of trials in other settings,
324 including those utilising these data for at least one trial outcome measure (14, 15), and for the long-
325 term extension of completed trials (16,17). These reviews identified similar types of trials accessing
326 RCHD, in terms of trial characteristics. However, due to the traditional literature searches employed
327 by these reviews, they identified only a handful of the UK trials identified here; by reviewing release
328 registers rather than publications we found more trials are receiving data than are mentioning it in
329 their publications.

330

331 Reliance on data provision from registries raises unpredictable, and potentially extremely time
332 consuming, challenges relating to data access and retention. For example, changes to registry names
333 can render participant consent invalid if it no longer references the correct provider name.

334 Individuals at registry organisations are also known to have provided contrary information on
335 specific consent form wording (19). Many researchers report long delays in the application process,
336 impacting on timely data collection and trial completion, with reports of RCTs being unable to
337 publish trial results due to issues with data access (20), and in one RCT failure to gain access to
338 mortality data has necessitated a change to the primary trial outcome measure (21). Cancer

339 registration data, collected by Public Health England, have previously been available through NHS
340 Digital, however provision of this data stopped for a period of more than two years. Such
341 unscheduled lapses in data availability introduce substantial risk for RCTs relying on these cancer
342 registration notifications through this route. One RCT reported failure by the registry to update
343 flagging of new patients as recruitment continued: the trial team received death information only for
344 the initial half of their cohort (22). Additionally, many registries do not permit ongoing retention or
345 onward sharing of the datasets, creating conflict with key trial processes such as data archiving, data
346 sharing and individual participant data meta-analysis (19, 23).

347 The administrative nature of some RCHD sources, the external coding and validation processes
348 employed, and lack of oversight and visibility of data collection, processing, and audit trails raise
349 concerning implications for Good Clinical Practice (GCP) adherence (24). The data used in clinical
350 trials have to be the same as the source data to be GCP compliant. There are accounts of data
351 quality issues from RCHD, even for clearly-objective outcome measures such as death (25-27)
352 though cardiovascular outcomes seem more promising (28). A standardised, systematic approach to
353 data quality assessment, ideally as a coordinated series of multi-RCT study-within-a-trial (SWAT),
354 would provide empirical evidence of the quality of RCHD and traditional trial data.. Registry
355 processes for data collection and editing would also need to be assessed.

356 The timeliness of RCHD is key. While primary care data, for example held by Clinical Practice
357 Research Datalink (CPRD), can be extracted easily from multiple GP practices across software
358 systems (Vision or EMIS), provision of secondary care data such as Hospital Episode Statistics
359 generally has delayed capture, and is received in batch files every month or quarter. Certainly these
360 data cannot be relied upon for the timely reporting of serious adverse events (e.g. requiring hospital
361 admission).

362 **Conclusion**

363 Only a tiny percentage of UK-based RCTs have accessed RCHD in the last five years to inform
364 participant data, and few of these are exclusively relying on RCHD, despite the fact that most patient
365 data are captured by hospital systems. Further, while most RCTs appear to be utilising similar
366 datasets from a small number of registries, the way in which the RCHD is used to inform or
367 supplement trial data appeared to vary substantially. Barriers to lack of utilisation include access to
368 data and fitness of RCHD for research purposes.

369 Our review supports concerns that exploiting the potential of RCHD in trials is hindered ([Table 5](#)).
370 Targeting resource to developing robust solutions to overcome these hurdles and enable a step
371 change for clinical trials is urgently needed such that UK trials can fully harness the power of RCHD
372 to conduct more efficient RCTs.

373

374

375 **List of abbreviations**

376

377 HDR UK - Health Data Research UK

378 NIHR - National Institute for Health Research

379 RCT – randomised controlled trial

380 RCHD – routinely-collected health data

381 UKCRC - UK Clinical Research Collaboration

382

383 Declarations

- 384 • Ethics approval and consent to participate

385 Not required as this was a review of RCTs accessing RCHD and no patient-level data were
386 used

- 387 • Consent for publication

388 Not applicable

- 389 • Availability of data and material

390 All of the information is publicly available. The dataset and technical appendices are
391 available upon request as per the controlled access approach of the MRC CTU at UCL. Please
392 contact the corresponding author for more information.

- 393 • Competing interests

394 All authors have completed the ICMJE uniform disclosure form at
395 www.icmje.org/coi_disclosure.pdf and declare: a grant from HDRUK to support this project.
396 MS reports grants from Health Data Research UK, during the conduct of the study; personal
397 fees from Lilly Oncology, personal fees from Janssen, grants and non-financial support from
398 Astellas, grants and non-financial support from Clovis Oncology, grants and non-financial
399 support from Janssen, grants and non-financial support from Novartis, grants and non-
400 financial support from Pfizer, grants and non-financial support from Sanofi-Aventis, outside
401 the submitted work. SBL reports travel and subsistence from Federal Drugs Agency, outside
402 the submitted work.

- 403 • Funding

404 This work was supported by Health Data Research UK, an initiative funded by UK Research
405 and Innovation, Department of Health and Social Care (England) and the devolved
406 administrations, and leading medical research charities, Medical Research Council
407 MC_UU_12023/24. The funding body had no direct involvement in the design, data
408 collection, analysis and interpretation or in writing the manuscript.

409 • Authors' contributions

410 SLe conceived the idea for the review, drafted the protocol, and drafted the manuscript. SLe,
411 VYE, SLo, MS, JC developed the protocol and planned the project. SLe, AM, VYE, SLo, EW, GP,
412 JC and MS performed screening and RCT identification. SLe, AM, VYE, SLo, EW, GP, MS, NN,
413 AB and MM performed data extraction. CDM lead the development of the computer
414 application used for data collection. SLe, SLo and VYE performed the data analysis. All
415 authors contributed to the paper writing and reviewed the last version of the manuscript.

416 • Acknowledgements

417 Thank you to the UKCRC Registered CTU Network and to all those who completed the
418 questionnaire.

419 • Authors' information

420 SBL, VYE, SL and MS are part of the MRC CTU at UCL Trial Conduct Team. RCHD is one of the
421 three streams of research from this team.

422

423

424

425

426

427

428

429

430 Additional files

431

Filename	File format	title	description
Additional file_1	docx	Table S1	Registries searched and approached
Additional file_2	docx	Table S2	Linkage identifier combinations by frequency of use (detailed extraction 2017-2018)
Additional File_3	docx	Table S3	Data use combinations by frequency of use, among trials using data for the primary report (n=74)

Additional file_4	docx	Appendix 1	Additional information about data collection
-------------------	------	------------	--

432

433 **REFERENCES**

- 434 1. Raftery J, Young A, Stanton L, Milne R, Cook A, Turner D, et al. Clinical trial metadata: defining and
435 extracting metadata on the design, conduct, results and costs of 125 randomised clinical trials
436 funded by the National Institute for Health Research Health Technology Assessment programme.
437 Health technology assessment (Winchester, England). 2015;19(11):1-138.
- 438 2. Lauer MS, D'Agostino RB, Sr. The randomized registry trial--the next disruptive technology in clinical
439 research? N Engl J Med. 2013;369(17):1579-81.
- 440 3. Wachtell K, Lagerqvist B, Olivecrona GK, James SK, Fröbert O. Novel Trial Designs: Lessons Learned from
441 Thrombus Aspiration During ST-Segment Elevation Myocardial Infarction in Scandinavia (TASTE)
442 Trial. Current Cardiology Reports. 2016;18(1):11.
- 443 4. Fröbert O, Lagerqvist B, Olivecrona GK, Omerovic E, Gudnason T, Maeng M, et al. Thrombus Aspiration
444 during ST-Segment Elevation Myocardial Infarction. N Engl J Med. 2013;369(17):1587-97.
- 445 5. <https://www.hdruk.ac.uk/research/research-priorities/21st-century-clinical-trials/> (accessed
446 10Mar2020 2020).
- 447
- 448 6. Benchimol EI, Smeeth L, Guttman A, Harron K, Moher D, Petersen I, et al. The REporting of studies
449 Conducted using Observational Routinely-collected health Data (RECORD) statement. PLoS Med.
450 2015;12(10):e1001885.
- 451 7. Health and Social Care Information Centre. Data Release Review 2014 [Available from:
452 [https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/367791/HSCIC_Data_Release_Review_PwC_Final_Report.pdf)
453 [e/367791/HSCIC_Data_Release_Review_PwC_Final_Report.pdf](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/367791/HSCIC_Data_Release_Review_PwC_Final_Report.pdf)].
- 454 8. Healthcare Quality Improvement Partnership. National Clinical Audits and Enquiries Directory 2019
455 [cited 2019 August 15]. Available from: [https://www.hqip.org.uk/resource/national-clinical-audit-](https://www.hqip.org.uk/resource/national-clinical-audit-and-enquiries-directory/#.XUALQvJKjcs)
456 [and-enquiries-directory/#.XUALQvJKjcs](https://www.hqip.org.uk/resource/national-clinical-audit-and-enquiries-directory/#.XUALQvJKjcs).

- 457 9. Elsevier. MACRO—advanced data collection for clinical research [Internet]. [cited 2019 August 15].
458 Available from: <https://www.elsevier.com/en-gb/solutions/macro>.
- 459 10. StataCorp. 2017. Stata Statistical Software: Release 15. College Station, TX: StataCorp LLC.
- 460 11. Clark T, Wicentowski RH, Sydes MR. Cross-sectional analysis of UK research studies in 2015: results from
461 a scoping project with the UK Health Research Authority. *BMJ Open*. 2018;8(10):e022340.
- 462 12. Harron K, Gamble C and Gilbert R. E-health data to support and enhance randomised controlled trials in
463 the United Kingdom. *Clinical Trials*. 2015;12(2):180-2.
- 464 13. Kwakkenbos L, Juszcak E, Hemkens LG, Sampson M, Fröbert O, Relton C, et al. Protocol for the
465 development of a CONSORT extension for RCTs using cohorts and routinely collected health data.
466 *Research Integrity and Peer Review*. 2018;3(1):9.
- 467 14. Mathes T, Buehn S, Prengel P, Pieper D. Registry-based randomized controlled trials merged the
468 strength of randomized controlled trails and observational studies and give rise to more pragmatic
469 trials. *Journal of clinical epidemiology*. 2018;93:120-7.
- 470 15. Mc Cord KA, Ewald H, Ladanie A, Briel M, Speich B, Bucher HC, et al. Current use and costs of electronic
471 health records for clinical trial research: a descriptive study. *CMAJ open*. 2019;7(1):E23-e32.
- 472 16. Fitzpatrick T, Perrier L, Shakik S, Cairncross Z, Tricco AC, Lix L, et al. Assessment of Long-term Follow-up
473 of Randomized Trial Participants by Linkage to Routinely Collected Data: A Scoping Review and
474 AnalysisLong-term Follow-up of Trial Participants by Linkage to Routinely Collected DataLong-term
475 Follow-up of Trial Participants by Linkage to Routinely Collected Data. *JAMA Network Open*.
476 2018;1(8):e186019-e.
- 477 17. Llewellyn-Bennett R, Edwards D, Roberts N, Hainsworth AH, Bulbulia R, Bowman L. Post-trial follow-up
478 methodology in large randomised controlled trials: a systematic review. *Trials*.2018;19:298
- 479 18. National Institute for Health Research (NIHR). Health Data Finder for Research [accessed 2019 August
480 15]. Available from: <http://www.hdf.nihr.ac.uk/>.

- 481 19. Lugg-Widger F, Angel L, Cannings-John R, Hood K, Hughes K, Moody G, et al. Challenges in accessing
482 routinely collected data from multiple providers in the UK for primary studies: Managing the
483 morass. *International Journal of Population Data Science*. 2018;3(3):1-14.
- 484 20. NHS Digital Release register archive. Register of approved data releases: 1 October to 31 December
485 2018 2018 [cited 2019 August 15]. Available from: [https://digital.nhs.uk/services/data-access-
486 request-service-dars/register-of-approved-data-releases/release-register-archive#2018](https://digital.nhs.uk/services/data-access-request-service-dars/register-of-approved-data-releases/release-register-archive#2018).
- 487 21. Peden CJ, Stephens T, Martin G, Kahan BC, Thomson A, Rivett K, et al. Effectiveness of a national quality
488 improvement programme to improve survival after emergency abdominal surgery (EPOCH): a
489 stepped-wedge cluster-randomised trial. *The Lancet*. 2019;393(10187):2213-21.
- 490 221. The INFANT Collaborative Group. Computerised interpretation of fetal heart rate during labour
491 (INFANT): a randomised controlled trial. *Lancet (London, England)*. 2017;389(10080):1719-29.
- 492 232. Drazen JM. Sharing Individual Patient Data from Clinical Trials. *New England Journal of Medicine*.
493 2015;372(3):201-2.
- 494 24. Martin J. Electronic health records [Internet]: MHRA Inspectorate. [cited 2019 August 15]. Available
495 from: <https://mhrainspectorate.blog.gov.uk/2019/07/23/electronic-health-records/>.
- 496 25. Brennan L, Watson M, Klaber R, Charles T. The importance of knowing context of hospital episode
497 statistics when reconfiguring the NHS. *BMJ : British Medical Journal*. 2012;344:e2432.
- 498 26. Hobson P, Meara J. Mortality and quality of death certification in a cohort of patients with Parkinson's
499 disease and matched controls in North Wales, UK at 18 years: a community-based cohort study. *BMJ
500 Open*. 2018;8(2):e018969.
- 501 27. Sington JD, Cottrell BJ. Analysis of the sensitivity of death certificates in 440 hospital deaths: a
502 comparison with necropsy findings. *Journal of clinical pathology*. 2002;55(7):499-502.

503 28. Rodrigues C, Odutayo A, Patel S, Agarwal A, Roza da Costa B, Lin E, et al. Comparison between
504 cardiovascular trial outcomes and treatment effects using clinical endpoint committee adjudication
505 versus routine health data: A Systematic Review. *JACC*. 2019;73(9):1753

506

507

508

509

510 **Table 1. Trial characteristics**

Trial characteristic		Summary extraction (2013-16) (n, %)	Detailed extraction (2017-18) (n, %)	Total (n, %)
		n=69	n=91	n=160
Purpose				
Screening		6 (9%)	10 (11%)	16 (10%)
Treatment		51 (74%)	65 (71%)	116 (73%)
Primary Prevention		12 (17%)	16 (18%)	28 (18%)
Feasibility/ Pilot Trial				
Yes		6 (9%)	11 (12%)	17 (11%)
No		63 (91%)	80 (88%)	143 (89%)
Recruitment Setting				
Primary Care		23 (33%)	18 (20%)	41 (26%)
Secondary Care		46 (67%)	73 (80%)	119 (74%)
Disease Category				
Cancer		17 (25%)	30 (33%)	47 (29%)
Cardiovascular and stroke		21 (30%)	25 (27%)	46 (29%)
Pregnancy and childbirth		4 (6%)	5 (5%)	9 (6%)
Mental/neurological health		6 (9%)	6 (7%)	12 (8%)
Infection		5 (7%)	3 (3%)	8 (5%)
Endocrine and diabetes		1 (1%)	3 (3%)	4 (3%)
Inflammatory disorder		2 (3%)	3 (3%)	5 (3%)
Other		13 (19%)	16 (18%)	29 (18%)
Intervention				
Drug		38 (55%)	38 (42%)	76 (48%)
Surgical		5 (7%)	8 (9%)	13 (8%)
Other		26 (38%)	45 (49%)	71 (44%)
Primary Outcome				
Survival related		33 (48%)	39 (43%)	72 (45%)
Other		36 (52%)	52 (57%)	88 (55%)
Randomisation				
Individual		61 (88%)	75 (82%)	136 (85%)
Cluster		8 (12%)	16 (18%)	24 (15%)
Trial Size	Median	1103	2611	1590
	Range	41-170432	53-6000000	41-6000000
	1-500	21 (30%)	20 (22%)	41 (26%)
	500-5000	31 (45%)	43 (47%)	74 (46%)
	>5000	17 (25%)	25 (27%)	42 (26%)
	Unclear	0 (0%)	3 (3%)	3 (2%)
International Accrual				
Yes		13 (19%)	19 (21%)	32 (20%)
No (UK only)		56 (81%)	69 (76%)	125 (78%)
Unclear		0 (0%)	3 (3%)	3 (2%)
Coordinated by Registered CTU				
Yes		40 (58%)	63 (69%)	103 (64%)
No		10 (14%)	12 (13%)	22 (14%)
Unclear		19 (28%)	16 (18%)	35 (22%)
Highest Profile Journal (if primary report published)				
BMJ		NA	2 (2%)	2 (1%)
JAMA		NA	6 (7%)	6 (4%)

Lancet	NA	16 (18%)	16 (10%)
Lancet-specialty	NA	2 (2%)	2 (1%)
NEJM	NA	3 (3%)	3 (2%)
Other	NA	6 (7%)	6 (4%)
Not yet published	NA	56 (62%)	56 (35%)
Not captured	69 (100%)	NA	69 (43%)

511

512

513 **Table 2. Comparison of RCTs accessing RCHD with trials evaluated by the HRA in 2015.**

	RCTs accessing RCHD (n=160)	HRA in 2015¹ (n=963²)
Recruitment setting		
Primary care	41 (26%)	48 (5%)
Secondary care	119 (74%)	846 (95%)
Unclear/missing	0	69
Therapeutic area		
Cancer	47 (29%)	168 (17%)
Cardiovascular and stroke	46 (29%)	121 (13%)
Pregnancy and childbirth	9 (6%)	30 (3%)
Infection	8 (5%)	55 (6%)
Inflammatory disorder	5 (3%)	72 (7%)
Drug trial	76 (48%)	515 (53%)
Randomisation		
Individual	136 (85%)	934 (97%)
Cluster trial	24 (15%)	29 (3%)
Feasibility/pilot	17 (11%)	177 (18%)
Sample size (median, range)	1590 (41 - 6,000,000)	275 (6 - 30,000)
Unclear/missing	0	440
Recruitment location		
UK only	125 (78%)	450 (50%)
International trials	32 (20%)	443 (50%)
Unclear/missing	0	70

514

515 Caption: This table only includes data fields which were comparable between the two sources.

516 Sample size targets in the HRA cohort are limited to those not described as phase I/II trials. Data

517 obtained from Clark et al 2018, including unpublished supplementary appendices (1).

518 ¹Clark T, Wicentowski RH, Sydes MR. Cross-sectional analysis of UK research studies in 2015: results
519 from a scoping project with the UK Health Research Authority. *BMJ Open*. 2018;8(10):e022340.

520

521 ²For recruitment setting and location, the unclear/missing values were omitted from the percentage
522 calculation

523

524 **Table 4. Categories describing how RCHD was used to inform or supplement participant data**

Data use category	Description	Example	All trials N=91	Primary N=74	Long-term follow-up N=52	Both N=36
1	The RCHD alone is used as trial data, with no cross-checking or comparison against any other data	One of the included RCTs was a cluster-randomised trial of GP practices. Outcome data specific to the trial were extracted at the level of the cluster (GP practice) from CPRD.	52 (57%)	33 (45%)	34 (65%)	15 (42%)
2	RCHD is used to cross-check against or verify known trial data i.e. data already being collected on CRFs as part of the trial (arising from clinical observations and measurements)	In one case, death and cause of death of participants are captured on CRFs at each site. NHS-Digital also send the trial team quarterly reports of all new deaths. The trial team then compare the events and cause of death from both sources.	27 (30%)	24 (32%)	6 (12%)	3 (8%)
3	RCHD is used to cross-check against or verify self-reported trial data i.e. data already being collected from participants, for example by questionnaire	In one trial, participants are asked to complete a questionnaire every 3 months which asks if they had any unexpected stays in hospital. This information is cross-checked against Hospital Episode Statistics data obtained from NHS-Digital.	28 (31%)	22 (30%)	11 (21%)	5 (14%)
4	RCHD is used to alert or flag trial teams to a potential outcome/event, prompting medical note review to confirm the outcome/event. The specific outcome/events being flagged are not otherwise being captured as trial data. This may be accompanied by clinical end-point review or adjudication of events and outcomes.	In one RCT, participants were flagged in the UK Transplant Registry for notification of transplant rejection and failure. When participants were identified as having a transplant rejection or failure, study staff sought extra information from hospital records. The collated information was redacted and used for central adjudication by trained clinicians.	22 (24%)	19 (26%)	9 (17%)	6 (17%)
5	RCHD from one source is used to cross-check against or compared with RCHD from another source	One of the included RCTs accessed RCHD from NHS-Digital, ICNARC and OHCAO, and all had provided the same fields - such as length of stay in intensive care.	9 (10%)	7 (9%)	6 (12%)	4 (11%)

6	RCHD is being used for health economic analysis or cost-effectiveness purposes, rather than a clinical outcome	In one study, Hospital Episode Statistics data was used to calculate the cost of secondary resource use within 90 days of randomisation	25 (27%)	21 (28%)	12 (23%)	8 (22%)
7	RCHD is not used directly for trial purposes, but to evaluate the quality of these data compared to trial data or other RCHD, or RCHD is used to generate an algorithm or equation that hopes to predict or replicate the frequency of events/outcomes.	In a breast cancer trial, cancer data from NCRAS were accessed and compared against the trial data to assess the completeness, validity, and consistency of the two data sources.	11 (12%)	11 (15%)	1 (2%)	1 (3%)
Unclear	-	-	13 (14%)	9 (12%)	9 (17%)	5 (14%)

525

526 Caption: These categories were developed for the purpose of this review, and are not mutually exclusive. For example, RCTs may use RCHD for both cross-
 527 checking against existing trial data and against a second source of RCHD. Additionally, RCTs may use RCHD from multiple sources in different ways.
 528 Percentages are calculated using the column header denominators.

529


530 Table 5: Barriers to use of routinely collected health data and potential solutions

Barrier	Example/explanation	Potential solution
Lack of comprehensive list of RCHD sources and the data they hold	There is no one point where you can find out about all sources of RCHD.	A searchable database, with HDRUK or NHS digital responsible for update
Clear terminology to describe data from registries	The source of the trial data is not always mentioned in trial publications.	Publication of consensus terminology and a description of the way in which RCHD can be used
Publications of trials using RCHD did not make mention of it	In methods section, details of the sources of RCHD should be stated.	Soon to be released EHR CONSORT extension for routinely collected health data should improve this
Lack of awareness by trialists of the availability and utility of RCHD	Shown by a few percent of trials using RCHD.	More publicity on available RCHD and the use of RCHD
Poor accessibility of data	Registry name change invalidating consent. Long delays of several years in application process. RCHD not provided despite agreement.	Streamline the RCHD application process and render it efficient
Poor data retention and no possibility of onward sharing	Time limit to keeping the data is shorter than the data storage time limit for the trial. Data sharing is often necessary to achieve funding for a trial.	RCHD needs to align with trial data retention rules and data sharing requirements
Data quality and timeliness	Trial data is monitored and checked and much registry data is not.	Registry data needs a validation process to ensure their RCHD can be used as a verifiable GCP-compliant data source A comparison of trial and registry data in several trials facilitated by a SWAT protocol to educate all about the accuracy and completeness of registry data
Regulator ready RCHD	Trial data requires underlying source data whilst registry data is not source data and does not often have checked underlying source data.	Regulators and registries need to agree a solution to underlying source data

531

532

533 Figure 1



534